65岁以上老年人接种戊肝疫苗的安全性与免疫原性
开放标签对照试验纳入601名参与者,其中200名>65岁老年人和201名18-65岁成人按0、1、6月接种Hecolin®,另200名>65岁老年人作为安全对照未干预。>65岁接种者中96.7%在末剂后1个月血清阳转,未报告疫苗相关严重不良事件,表明Hecolin®在>65岁老年人中具有免疫原性且耐受良好。
要点
- >65岁老年人接种3剂Hecolin®后96.7%血清阳转。
- 基线血清阴性者抗HEV IgG几何均浓度为5.36(95%CI 3.88-7.41)。
- 无疫苗相关严重不良事件报告,耐受性良好。
核心结论
- Hecolin®在>65岁老年人中具有免疫原性且耐受良好。
研究设计与样本
- 开放标签、对照试验,共纳入601名符合条件参与者。
- 200名>65岁老年人和201名18-65岁成人按0、1、6月接种Hecolin®。
- 另200名>65岁老年人作为安全对照,未干预但按相同方式报告不良事件。
- 接种前(第0天)及第7月采集血清检测抗HEV IgG。
主要发现
- >65岁接种者完成3剂标准程序后,96.7%在末剂后1个月(第7月)血清阳转。
- 第7月时,基线血清阴性>65岁老年人抗HEV IgG几何均浓度为5.36(95%CI 3.88-7.41)。
- 第7月时,基线血清阳性>65岁老年人抗HEV IgG几何均浓度为19.65(95%CI 16.81-22.98)。
- 97.3%(177/182)的>65岁接种者第7月抗HEV IgG水平高于1.0 WU/ml。
- 未报告疫苗相关严重不良事件。
关键数值与推荐
- >65岁老年人按0、1、6月接种3剂Hecolin®后,96.7%血清阳转。
- 基线血清阴性>65岁老年人第7月抗HEV IgG几何均浓度为5.36(95%CI 3.88-7.41)。
- 基线血清阳性>65岁老年人第7月抗HEV IgG几何均浓度为19.65(95%CI 16.81-22.98)。
- 97.3%(177/182)的>65岁接种者第7月抗HEV IgG水平高于1.0 WU/ml。
临床怎么用
- 对于>65岁老年人,可按0、1、6月标准程序接种Hecolin®以诱导抗HEV IgG应答。
- 接种后多数>65岁老年人可达到血清阳转,且未报告疫苗相关严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis E virus (HEV) infection is a leading cause of acute hepatitis worldwide, and results in high morbidity and mortality rates among elderly people in China. The hepatitis E vaccine, Hecolin®, has been shown to be safe and highly efficacious among healthy adults aged 16-65 years old. However, there is no data about Hecolin® vaccination in elderly people older than 65 years (y). METHODS: An open-labeled, controlled trial was conducted to evaluate the safety and immunogenicity of Hecolin® among the elderly aged >65 y. A total of 601 eligible participants were enrolled. Among them, 200 elderly people aged >65 y and 201 adults aged 18-65 y were assigned to the Hecolin® groups and vaccinated at day 0, month 1 and month 6. Serum samples were collected for anti-HEV IgG determination at day 0 prior to immunization and at month 7. The remaining 200 elderly people aged >65 y were assigned to the safety control group and received no intervention but were instructed to report any adverse events that occurred during the whole study period in the same way as those in the Hecolin® groups. RESULTS: After receiving 3 doses of Hecolin® with the standard schedule, most (96.7%) of the vaccinated elderly people aged >65 y seroconverted at one month after the final dose (month 7). At month 7, the geometric mean concentrations of anti-HEV IgG were 5.36 (95% CI, 3.88-7.41) and 19.65 (95% CI, 16.81-22.98) among the baseline seronegative and seropositive elderly, respectively. Of the vaccinated elderly, 97.3% (177/182) had anti-HEV IgG levels higher than 1.0 WU/ml at month 7. Hecolin® was very well tolerated in this population. No vaccine-related SAEs were reported. CONCLUSIONS: Hecolin® is immunogenic and well tolerated in elderly people aged greater than 65 years.
引用
- Yu XY, Chen ZP, Wang SY, et al. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years. Vaccine. 2019. PMID: 31262585. doi:10.1016/j.vaccine.2019.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。